- Evolus (EOLS, Financial) has launched Nuceiva® in France through a strategic partnership with Symatese.
- Nuceiva® is approved for reducing moderate to severe glabellar lines in adults under 65.
- This move is part of Evolus' global expansion strategy, targeting the growing aesthetics market in Europe.
Evolus, Inc. (EOLS), a performance beauty company, has unveiled its latest expansion into the French market with the introduction of Nuceiva® (botulinum toxin type A). In collaboration with Symatese, a prominent French company with deep roots in the aesthetics industry, Evolus aims to serve French medical aesthetics professionals by enabling direct order and delivery of the product.
Nuceiva®, which is known as Jeuveau® in the United States, has been approved by the European Commission for the temporary improvement of moderate to severe glabellar lines—a common cosmetic concern. This product launch underscores Evolus' commitment to strategic geographical expansion, with France representing a key growth market for the company.
David Moatazedi, President and CEO of Evolus, remarked on this achievement, emphasizing the milestone as part of their broader international growth strategy. Symatese, with its extensive expertise in regenerative medical solutions and strong relationships with French aesthetic clinicians, is well-positioned as the exclusive distributor of Nuceiva® in France.
Dr. Patrick Trevidic, a renowned aesthetic surgeon based in Paris, highlighted the significant transformation in Europe's aesthetics market. He noted how Nuceiva® provides practitioners with enhanced treatment options, appealing particularly to the younger generation seeking non-surgical cosmetic solutions.
The safety and efficacy of Nuceiva® were confirmed through Evolus' TRANSPARENCY clinical program, which included several Phase III trials. The product has shown comparable side effects to others within its class, affirming its safety profile.
